77 studies found for:    MEK Inhibitor AZD-6244
Show Display Options
Rank Status Study
1 Completed A Randomized, Open Label Study to Compare the Current Phase II and Planned Phase III Capsule Formulation of AZD6244
Condition: Healthy Volunteers
Interventions: Drug: AZD6244 Dosing Period 1;   Drug: AZD6244 Dosing Period 2;   Drug: AZD6244 Dosing Period 3;   Drug: AZD6244 Dosing Period 4
2 Completed Reacquisition of Radioactive Iodine (RAI) Uptake of RAI-Refractory Metastatic Thyroid Cancers by Pretreatment With the Selective MEK Inhibitor AZD6244
Condition: Thyroid Cancer
Intervention: Biological: AZD6244
3 Completed To Assess the Effect of Itraconazole and Fluconazole on the Pharmacokinetics of Selumetinib in Healthy Male Volunteers
Condition: Solid Tumours
Interventions: Drug: selumetinib;   Drug: itraconazole;   Drug: fluconazole
4 Completed To Assess the Effect of Rifampicin on the Pharmacokinetics of Selumetinib in Healthy Male Volunteers
Condition: Solid Tumours
Interventions: Drug: selumetinib;   Drug: rifampicin
5 Completed To Assess the Effects of Single Oral Dose of Selumetinib [AZD6244; ARRY-142886] [Hyd-Sulfate]), on QTc Interval in Healthy Male Volunteers
Condition: Solid Tumours
Interventions: Drug: Selumetinib;   Drug: Moxifloxacin;   Drug: selumetinib
6 Not yet recruiting A Study to Assess the Absolute Bioavailability of Oral Selumetinib in Healthy Male Volunteers.
Condition: Healthy Volunteers Bioavailability Study
Interventions: Drug: selumetinib 75mg single dose;   Other: [14C] selumetinib IV solution
7 Recruiting MEK Inhibitor and Thoracic Radiotherapy Trial
Condition: Non Small Cell Lung Cancer
Intervention: Drug: AZD6244
8 Active, not recruiting A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)
Conditions: Breast Cancer;   Breast Neoplasms;   Colon Cancer;   Colonic Cancer;   Colon Neoplasms;   Lung Cancer;   Melanoma;   Kidney Cancer
Interventions: Drug: AZD6244;   Drug: Dacarbazine;   Drug: Erlotinib;   Drug: Docetaxel;   Drug: Temsirolimus
9 Completed Randomised Study to Compare the Efficacy of AZD6244 vs TMZ
Condition: Melanoma
Interventions: Drug: AZD6244;   Drug: Temozolomide
10 Active, not recruiting AZD6244 (Selumetinib, ARRY142886) J-BTC Phase 1 Study
Condition: Inoperable Locally Advanced or Metastatic Biliary Tract Cancer
Interventions: Drug: Cisplatin;   Drug: Gemcitabine;   Drug: Selumetinib
11 Completed Selumetinib and Cetuximab in Treating Patients With Refractory Solid Tumors
Conditions: Recurrent Colon Cancer;   Recurrent Rectal Cancer;   Stage IVA Colon Cancer;   Stage IVA Rectal Cancer;   Stage IVB Colon Cancer;   Stage IVB Rectal Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: selumetinib;   Biological: cetuximab;   Other: laboratory biomarker analysis;   Other: pharmacological study
12 Completed To Assess the Effect of Food on the Pharmacokinetics of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Healthy Male Volunteers
Condition: Solid Tumours
Intervention: Drug: selumetinib (oral)
13 Recruiting A Study of Selumetinib in Patients With Kaposi's Sarcoma
Condition: AIDS-related Kaposi's Sarcoma
Intervention: Drug: Selumetinib
14 Terminated Selumetinib in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma
Condition: Recurrent Adult Diffuse Large Cell Lymphoma
Interventions: Drug: selumetinib;   Other: laboratory biomarker analysis
15 Completed Dose-escalation Study to Assess Selumetinib Safety, Tolerability and PK
Condition: Healthy Volunteers Pharmacokinetic Study
Intervention: Drug: Selumetinib
16 Active, not recruiting Selumetinib and Cixutumumab in Treating Patients With Advanced Solid Malignancies
Condition: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: selumetinib;   Biological: cixutumumab;   Other: pharmacological study;   Other: laboratory biomarker analysis
17 Active, not recruiting AZD6244 and Sorafenib in Advanced Hepatocellular Carcinoma
Conditions: Unresectable Hepatocellular Carcinoma;   Liver Cancer
Intervention: Drug: AZD6244 and sorafenib
18 Recruiting Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC
Condition: Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV
Interventions: Drug: Selumetinib;   Drug: Docetaxel;   Drug: Placebo;   Drug: Pegylated G-CSF
19 Recruiting Assess Safety & Efficacy of Selumetinib When Given in Combination With Standard First Line Treatment for Advanced Non-small Cell Lung Cancer
Condition: Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIB -IV
Interventions: Drug: selumetinib;   Drug: gemcitabine;   Drug: cisplatin;   Drug: carboplatin;   Drug: pemetrexed
20 Completed Study Evaluating Absorption, Distribution, Metabolism and Excretion (ADME) of Single Dose [14C] Selumetinib in Volunteers
Condition: Solid Tumours
Intervention: Drug: [C14] selumetinib (oral)

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years